BioSpace News Archive

Zymeworks Inc. (Nasdaq: ZYME) today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a summary of recent business highlights.

IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m. ET.

IO Biotech (Nasdaq: IOBT) today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Protagonist Therapeutics, Inc. announced that they will participate in three upcoming investor conferences.

Guardant Health, Inc. announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 29,048 shares of its common stock to one new non-executive employee with a grant date of February 26, 2024 under the Guardant Health, Inc.

Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.

SciSparc Ltd. announced its had been received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment.

BioVie Inc. announced the closing of its previously announced best efforts public offering of 15,000,000 shares of its common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock and warrants to purchase up to 10,500,000 shares of common stock at a combined public offering price of $1.00 per share and associated Common Warrant.

Avinger, Inc. announced a new strategic partnership with Zylox-Tonbridge Medical Technology Co., Ltd., a leading medical device company in the neuro- and peripheral-vascular interventional market in China.

Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.